Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PQ Grass in Seasonal Allergic Rhinitis
NCT05540717Phase 3Completed
- Sponsor
- Allergy Therapeutics PLC
- Start
- Oct 2022
- Primary completion
- Nov 2023
- Modality
- Allergy Immunotherapy
- Countries
- 6
01
Overview
A Phase 3 trial of Grass MATA MPL in seasonal allergic rhinitis (SAR), Rhinoconjunctivitis (RC), sponsored by Allergy Therapeutics PLC. Started Oct 2022; status: completed.
02
Drugs
Grass MATA MPL
03
Conditions
seasonal allergic rhinitis (SAR)Rhinoconjunctivitis (RC)
Beyond the preview
Go deeper on NCT05540717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05540717.